Agnostic drug development revisited
The advent and rapid implementation of tissue-based or circulating tumor DNA next generation sequencing (NGS) in the clinic has enabled the identification of novel actionable genomic alterations present across tumor types[1]. Moreover, the number of agents approved that target specific actionable alterations has also increased enabling a shift in cancer treatment towards more personalized approaches paving the way for the implementation of precision oncology[2]. To date, a number of agents that target specific actionable alterations have shown superiority over standard-of-care cytotoxic agents and are part of the treatment armamentarium in a variety of cancers[3–6].